trial

D-Serine Monotherapy for Schizophrenia

NCTId NCT00215917
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 40
Sponsored by Herzog Hospital
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
40
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
—
Primary completion
—
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
D-serine 2100 mg daily

Sponsors

Herzog HospitalLead Sponsor

Investigators

1
Pesach Lichtenberg, M.D.Principal Investigator

Sites

1 total
Jerusalem, Israel

Facts & assertions

3 sourced
Enrollment
40
Phase
PHASE1,PHASE2
Status
UNKNOWN
relationships
The graph out of here
drug
D-serine 2100 mg daily
drug
lead_sponsor
Herzog Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Pesach Lichtenberg, M.D.
person